Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452774 · ClinicalTrials.gov registry record
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A clinical trial of Cancer and Cancer Metastatic, sponsored by Massive Bio.
- Recruiting
- Registry status
- 50,000
- Enrollment target
- 20
- Study locations
NCT03452774: Recruiting study of Cancer and Cancer Metastatic, sponsored by Massive Bio.
NCT03452774 is a study of Cancer and Cancer Metastatic that is actively recruiting participants, run by Massive Bio. The registered enrollment target is 50,000 participants, above the 3,410-participant average among 615 other Cancer trials with a reported enrollment target (1366% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03452774, a study of Cancer and Cancer Metastatic, is actively recruiting participants, sponsored by Massive Bio.
- RECRUITING
- Registry status
- 50,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Primary Outcome
CTE Accrual
Conditions Studied
Interventions
- OTHER Clinical Trial Matching
Study Locations (20)
California
- Massive Bio SYNERGY-AI site - Duarte
- Massive Bio SYNERGY-AI site - Irvine
- Massive Bio SYNERGY-AI site - La Jolla
- Massive Bio SYNERGY-AI site - Orange
- Massive Bio SYNERGY-AI site - San Francisco
- Massive Bio SYNERGY-AI site - Stanford
Colorado
- Massive Bio SYNERGY-AI site - Aurora
- Massive Bio SYNERGY-AI site - Denver
- Massive Bio SYNERGY-AI site - Littleton
Florida
- Massive Bio SYNERGY-AI site - Jacksonville
- Massive Bio SYNERGY-AI site - Miami
- Massive Bio SYNERGY-AI site - Tampa
Alabama
- Massive Bio SYNERGY-AI site - Birmingham
- Massive Bio SYNERGY-AI site - Mobile
Connecticut
- Massive Bio SYNERGY-AI site - Hartford
- Massive Bio SYNERGY-AI site - Norwalk
Arizona
- Massive Bio SYNERGY-AI site - Scottsdale
Arkansas
- Massive Bio SYNERGY-AI site - Little Rock
Delaware
- Massive Bio SYNERGY-AI site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50,000 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2040-06 |
What NCT03452774 shows while recruiting
NCT03452774 is an observational study that tracks outcomes without assigning an intervention. Its 50,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,410-participant average among 615 other Cancer trials with a reported enrollment target (1366% higher).
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Clinical Trial Matching is the first listed.
NCT03452774 names 20 study sites across 9 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT03452774 about?
NCT03452774 is a clinical study titled "SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry". International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical ...
What is the current status of trial NCT03452774?
This trial is currently recruiting. The enrollment target is 50,000 participants. The study started on 2018-01-01. Estimated completion is 2040-06.
What conditions does trial NCT03452774 study?
This clinical trial studies the following conditions: Cancer, Cancer Metastatic, Cancer of Pancreas, Cancer of Esophagus, Cancer of Liver.
What interventions are being tested in trial NCT03452774?
The interventions under investigation include: Clinical Trial Matching (OTHER).
Who is sponsoring clinical trial NCT03452774?
This trial is sponsored by Massive Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03452774 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03452774's enrollment target sits among peer trials
50,000 8th of 615 higher than 606 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- NCT04629586 · 50,000 participants
The T1D Exchange Registry
- NCT05497518 · 50,000 participants
The KidneyCARE (Community Access to Research Equity) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI